| 2017 | 2016 (revised) |
2015 (revised) |
||||||||||
|
Segment profit |
£m | £m | £m | |||||||||
|
Pharmaceuticals |
8,667 | 7,976 | 6,449 | |||||||||
|
Pharmaceuticals R&D |
(2,740 | ) | (2,488 | ) | (2,168 | ) | ||||||
|
|
|
|
|
|
|
|||||||
|
Pharmaceuticals, including R&D |
5,927 | 5,488 | 4,281 | |||||||||
|
Vaccines |
1,644 | 1,429 | 958 | |||||||||
|
Consumer Healthcare |
1,373 | 1,116 | 684 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Segment profit |
8,944 | 8,033 | 5,923 | |||||||||
|
Corporate and other unallocated costs |
(376 | ) | (362 | ) | (264 | ) | ||||||
|
Other reconciling items between segment profit and operating profit |
(4,481 | ) | (5,073 | ) | 4,663 | |||||||
|
|
|
|
|
|
|
|||||||
|
Operating profit |
4,087 | 2,598 | 10,322 | |||||||||
|
Finance income |
65 | 72 | 104 | |||||||||
|
Finance costs |
(734 | ) | (736 | ) | (757 | ) | ||||||
|
Profit on disposal of interest in associates |
94 | – | 843 | |||||||||
|
Share of after tax profits of associates and joint ventures |
13 | 5 | 14 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Profit before taxation |
3,525 | 1,939 | 10,526 | |||||||||
|
Taxation |
(1,356 | ) | (877 | ) | (2,154 | ) | ||||||
|
|
|
|
|
|
|
|||||||
|
Profit after taxation for the year |
2,169 | 1,062 | 8,372 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Depreciation and amortisation by segment |
2017 £m |
2016 £m |
2015 £m |
|||||||||
|
Pharmaceuticals |
551 | 440 | 303 | |||||||||
|
Pharmaceuticals R&D |
96 | 211 | 238 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Pharmaceuticals, including R&D |
647 | 651 | 541 | |||||||||
|
Vaccines |
405 | 315 | 253 | |||||||||
|
Consumer Healthcare |
135 | 126 | 140 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Segment depreciation and amortisation |
1,187 | 1,092 | 934 | |||||||||
|
Corporate and other unallocated depreciation and amortisation |
144 | 94 | 145 | |||||||||
|
Other reconciling items between segment depreciation and amortisation and total depreciation and amortisation |
591 | 588 | 551 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Total depreciation and amortisation |
1,922 | 1,774 | 1,630 | |||||||||
|
|
|
|
|
|
|
|||||||
|
PP&E, intangible asset and goodwill impairment by segment |
2017 £m |
2016 £m |
2015 £m |
|||||||||
|
Pharmaceuticals |
38 | 29 | 57 | |||||||||
|
Pharmaceuticals R&D |
10 | 88 | 105 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Pharmaceuticals, including R&D |
48 | 117 | 162 | |||||||||
|
Vaccines |
13 | 34 | 17 | |||||||||
|
Consumer Healthcare |
10 | 46 | 5 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Segment impairment |
71 | 197 | 184 | |||||||||
|
Corporate and other unallocated impairment |
3 | 24 | 18 | |||||||||
|
Other reconciling items between segment impairment and total impairment |
995 | 68 | 385 | |||||||||
|
|
|
|
|
|
|
|||||||
|
Total impairment |
1,069 | 289 | 587 | |||||||||
|
|
|
|
|
|
|
|||||||
|
PP&E and intangible asset impairment reversals by segment |
2017 £m |
2016 £m |
2015 £m |
|||||||||
|
Pharmaceuticals |
(13 | ) | (15 | ) | (8 | ) | ||||||
|
Pharmaceuticals R&D |
(2 | ) | (10 | ) | (10 | ) | ||||||
|
|
|
|
|
|
|
|||||||
|
Pharmaceuticals, including R&D |
(15 | ) | (25 | ) | (18 | ) | ||||||
|
Vaccines |
– | (19 | ) | – | ||||||||
|
Consumer Healthcare |
(1 | ) | (8 | ) | (4 | ) | ||||||
|
|
|
|
|
|
|
|||||||
|
Segment impairment reversals |
(16 | ) | (52 | ) | (22 | ) | ||||||
|
Corporate and other unallocated impairment reversals |
– | (26 | ) | (2 | ) | |||||||
|
Other reconciling items between segment impairment reversals and total impairment reversals |
(36 | ) | (9 | ) | – | |||||||
|
|
|
|
|
|
|
|||||||
|
Total impairment reversals |
(52 | ) | (87 | ) | (24 | ) | ||||||
|
|
|
|
|
|
|
|||||||
| 2017 | 2016 | |||||||
|
Net assets by segment |
£m | £m | ||||||
|
Pharmaceuticals |
2,017 | 3,225 | ||||||
|
Pharmaceuticals R&D |
522 | 572 | ||||||
|
|
|
|
|
|||||
|
Pharmaceuticals, including R&D |
2,539 | 3,797 | ||||||
|
Vaccines |
9,707 | 9,676 | ||||||
|
Consumer Healthcare |
2,003 | 3,721 | ||||||
|
|
|
|
|
|||||
|
Segment net operating assets |
14,249 | 17,194 | ||||||
|
Corporate and other unallocated net operating assets |
868 | (228 | ) | |||||
|
|
|
|
|
|||||
|
Net operating assets |
15,117 | 16,966 | ||||||
|
Net debt |
(13,178 | ) | (13,804 | ) | ||||
|
Investments in associates and joint ventures |
183 | 263 | ||||||
|
Derivative financial instruments |
2 | (38 | ) | |||||
|
Current and deferred taxation |
1,252 | 1,361 | ||||||
|
Assets held for sale |
113 | 215 | ||||||
|
|
|
|
|
|||||
|
Net assets |
3,489 | 4,963 | ||||||
|
|
|
|
|
|||||